natgillin/translations-raw huggingface dataset:
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/029-031(30/60/100tablets in Unit dose Blister)
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/029-031(30/60/100 tablet v enoodmernih pretisnih omotih)
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/038-040 (30/60/100tablets in Unit dose Blister)
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/022-028 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/038-040 (30/60/100 tablet v enoodmernih pretisnih omotih)
MARKETING AUTHORISATION NUMBER(S) EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablets in PVC/alu Blister) EU/1/11/712/032-034 (30/60/100tablets in Unit dose Blister)
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/11/712/008-014 (10/20/30/50/60/100/200 tablet v pretisnih omotih iz PVC-ja/aluminija) EU/1/11/712/032-034 (30/60/100 tablet v enoodmernih pretisnih omotih)
NAME OF THE MEDICINAL PRODUCT Levetiracetam Accord 1000 mg film-coated tablets Levetiracetam STATEMENT OF ACTIVE SUBSTANCE (S) Each film-coated tablet contains 1000 mg levetiracetam.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 1.000 mg levetiracetama.
Each film-coated tablet contains 750 mg levetiracetam.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 750 mg levetiracetama
5 to 10 mg /kg (0.05 to 0.10 ml/kg) twice daily
5 do 10 mg/kg (0,05 do
--1 Live attenuated avian infectious bronchitis virus (IBV), variant strain 4-91: ≥3.6 log10 EID50* per dose * EID50: 50% embryo infective dose - the virus titre required to produce infection in 50% of the embryos inoculated.
--1 Živi, oslabljeni variantni sev virusa kužnega bronhitisa perutnine (IBV) 4-91: ≥ 3,6 log 10 EID50* na odmerek * EID50: 50-odstotni infektivni odmerek za zarodke - titer virusa, ki povzroči okužbo pri 50 % inokuliranih zarodkov
3 Bottles
3 kapalni vsebniki
1 Bottle
1 kapalni vsebnik
If so, treatment should be stopped immediately.
Če se to zgodi, je treba takoj prekiniti zdravljenje.
After 3 weeks a break of at least 2 weeks is required.
Po treh tednih je potreben premor vsaj dveh tednov.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
To pomeni, da obstajajo podatki v literaturi z znanstvenimi dokazi o njihovi učinkovitosti in varnosti pri uporabi na navedene načine, ki zajemajo obdobje vsaj 10 let v EU.
In rare cases allergic skin reactions can occur.
V redkih primerih lahko pride do alergijskih kožnih reakcij.
Capsicum should only be used in adults over the age of 18 years and should not be used continuously for more than 3 weeks.
Plodovi paprike se smejo uporabljati samo pri odraslih, starejših od 18 let, in se ne smejo uporabljati neprekinjeno več kot tri tedne.
Overstimulating the receptors makes them become ‘desensitised' and no longer able to respond to the stimuli that normally cause pain.
Receptorji s čezmernim spodbujanjem postanejo „desenzibilizirani“ in se ne morejo več odzivati na dražljaje, ki navadno povzročajo bolečino.
This means that it stimulates the TRPV1 receptor, which is found in the nociceptors (pain receptors) in the skin.
To pomeni, da spodbuja receptor TRPV1, ki ga najdemo v nociceptorjih (receptorjih za bolečino) v koži.
Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus
Capsicum annuum L. var. minimum (Miller) Heiser in različice z majhnimi plodovi Capsicum frutescens L. , fructus
This summary is not intended to provide practical advice on how to use medicines containing capsicum.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo plod paprike.
Capsicum contains a substance known as capsaicin.
Plod paprike vsebuje snov, imenovano kapsaicin.
The capsaicin is used to overstimulate the TRPV1 receptors.
Kapsaicin se uporablja za čezmerno spodbujanje receptorjev TRPV1.
Capsaicin is a selective agonist of the ‘transientreceptor-potential-vanilloid-1' (TRPV1) receptor.
Kapsaicin je selektivni agonist „vaniloidnega receptorja TRP podtipa 1“ (TRPV1).
The HMPC conclusions on the use of capsicum medicines relief of muscle pain are based on their ‘wellestablished use' in this condition.
Zaključki odbora HMPC o uporabi zdravil za lajšanje mišične bolečine, ki vsebujejo plod paprike, temeljijo na njihovi „dobro uveljavljeni medicinski uporabi“ pri tem stanju.
Further information on the risks associated with capsicum medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo plod paprike, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Capsicum preparations are obtained by ethanol or propanol extraction (a technique used to extract compounds from plant parts by dissolving them in alcohol).
Pripravki plodov paprike se pridobijo z ekstrakcijo s pomočjo etanola ali propanola (tehniko, ki se uporablja za ekstrakcijo snovi iz rastlinskih delov z raztapljanjem v alkoholu).
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of capsicum.
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo plodov paprike.
The HMPC concluded that, on the basis of its well-established use, capsicum can be used for the relief of muscle pain, such as low back pain.
Odbor HMPC je zaključil, da se lahko plod paprike na podlagi dobro uveljavljene medicinske uporabe uporablja za lajšanje mišičnih bolečin, kot so bolečine v spodnjem delu hrbta.
In its assessment, the HMPC considered a number of clinical studies which showed improvements in pain relief following treatment with capsicum medicated plaster and skin preparations compared with placebo (a dummy treatment).
Pri svoji oceni je odbor HMPC upošteval številne klinične študije, ki so pokazale pomembno lajšanje bolečine pri zdravljenju z zdravilnimi obliži in pripravki za kožo, ki vsebujejo plod paprike, v primerjavi s placebom (zdravilom brez zdravilne učinkovine).
Capsicum is the common name for the fruits of the plant Capsicum annuum L. var. minimum (Miller) Heiser and Capsicum frutescens L. These are types of peppers that are cultivated or gathered to obtain the plant parts for medicinal use.
Plod paprike je splošno ime za sadeže rastlin Capsicum annuum L. var. minimum (Miller) Heiser in Capsicum frutescens L. To so vrste paprike, ki se gojijo ali nabirajo za pridobivanje delov rastline za medicinsko uporabo.
How does capsicum work as a medicine?
Kako plod paprike deluje kot zdravilo?
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing capsicum.
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo plod paprike.
Any applications for the licensing of medicines containing capsicum have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo plod paprike, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Further information on the HMPC assessment of capsicum medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dodatne informacije o oceni zdravil, ki vsebujejo plod paprike, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom »Vsi dokumenti«: ema.europa.eu/Find medicine/Herbal medicines for human use.
Information on the use and licensing of capsicum medicines in EU Member States should be obtained from the relevant national authorities.
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo plod paprike, v državah članicah EU se obrnite na pristojni nacionalni organ.
Herbal medicines containing capsicum are usually available in a medicated plaster or in semi-solid forms to be applied to the skin (such as creams).
Zdravila rastlinskega izvora, ki vsebujejo plod paprike, so navadno na voljo kot zdravilni obliži ali poltrdne oblike, ki se nanašajo na kožo (kot so kreme).
How are capsicum medicines approved in the EU?
Kako so zdravila, ki vsebujejo plod paprike, odobrena v EU?
Detailed instructions on how to use capsicum medicines and who can use them can be found in the package leaflet that comes with the medicine.
Podrobna navodila o tem, kako uporabljati zdravila, ki vsebujejo plod paprike in kdo jih sme uporabljati, so v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
Capsicum
Plod paprike
What evidence supports the use of capsicum medicines?
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo plod paprike?
Other information about capsicum medicines
Druge informacije o zdravilih, ki vsebujejo plod paprike
Capsicum medicines can cause reddening and a burning sensation on the areas of the skin where they are applied.
Zdravila, ki vsebujejo plod paprike, lahko povzročajo pordelost in pekoč občutek na delih kože, kamor se nanesejo.
For more information about treatment with capsicum medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravili, ki vsebujejo plod paprike, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
Capsicum medicines must not be used in patients allergic to other sources of capsaicin and capsaicinlike compounds (e.g. paprika or chilli) and must not be applied onto broken skin, wounds and eczema.
Zdravila, ki vsebujejo plod paprike, se ne smejo uporabljati pri bolnikih, alergičnih na druge vire kapsaicina in kapsaicinu podobne snovi (npr. papriko ali čili).
What are the risks associated with capsicum medicines?
Kakšna tveganja so povezana z zdravili, ki vsebujejo plod paprike?
For practical information about using capsicum medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
What is capsicum?
Kaj je plod paprike?
Interactions with other medical products and other forms of interaction:
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij:
Rectal temperatures should then return to normal values.
Nato se rektalna temperatura vrne na normalno vrednost.
Adjuvants: Aluminium hydroxide (Al3+)
aluminijev hidroksid (Al3+)
*(Cycling value (Ct) ≥ 36 by a validated RT-PCR method, indicating no presence of viral genome)
*(Ciklična vrednost (Ct) ≥ 36 pri validirani metodi RT-PCR, kar kaže, da virusni genom ni prisoten)
Pharmacotherapeutic group: Inactivated viral vaccines - Bluetongue virus.
Farmakoterapevtska skupina: Inaktivirana virusna cepiva - virus bolezni modrikastega jezika.
Administer one dose of 2 ml according to the following vaccination scheme: 1st injection: from 2.5 months of age.
Dajte en odmerek (2 ml) v skladu z naslednjim programom cepljenja: 1. injekcija: od 2,5 meseca starosti.
No information is available on the use of the vaccine in animals with maternally derived antibodies.
Na voljo ni nobenih informacij o uporabi cepiva pri živalih z maternalnimi protitelesi.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 05/08/2011
Datum pridobitve dovoljenja za promet: 05/08/2011 Datum zadnjega podaljšanja dovoljenja za promet: 18/04/2016
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. Once broached use immediately.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po {EXP}.Načeto uporabite takoj.
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of the immunological veterinary medicinal products on the whole or part of their territory if it is established that:
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta, z vsemi dopolnitvami in spremembami lahko država članica, skladno z nacionalno zakonodajo, prepove izdelavo, uvoz/vnos,
A slight to moderate increase of local reactions may commonly be observed after a 2-fold overdose lasting for a maximum of 56 days.
Pri 2-krat prevelikem odmerku se lahko pogosto opazi blago do zmerno povečanje lokalnih reakcij, ki trajajo največ 56 dni.
Duration of immunity: 12 months after completion of the primary vaccination course.
Trajanje imunosti: 12 mesecev po končanem osnovnem cepljenju.
Potassium dihydrogen phosphate Disodium hydrogen phosphate dodecahydrate Sodium chloride
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi aluminijev hidroksid saponin tiomersal kalijev klorid kalijev dihidrogenfosfat natrijev hidrogenfosfat dodekahidrat natrijev klorid
PACKAGE LEAFLET: Zulvac1 Bovis suspension for injection for cattle
NAVODILO ZA UPORABO Zulvac 1 Bovis suspenzija za injiciranje za govedo
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton 1 x 20ml, 1 x 100ml and 1 x 240ml
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla 1 x 20 ml, 1 x 100 ml in 1 x 240 ml
Onset of immunity: 15 days after completion of the primary vaccination scheme.
Nastop imunosti: 15 dni po osnovnem programu cepljenja.
For active immunisation of cattle from 2 and a half months of age for the prevention* of viraemia caused by Bluetongue Virus (BTV), serotypes 1.
Za aktivno imunizacijo goveda, starejšega od 2 in pol meseca starosti, za preprečitev* viremije, ki jo povzroča virus bolezni modrikastega jezika, serotip 1.
EXPIRY DATE EXP {month/year} Once broached use immediately.
EXP {mesec/leto} Načeto uporabite takoj.
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1
inaktiviran virus bolezni modrikastega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP*≥1
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 Aluminium hydroxide, saponin and thiomersal.
V odmerku 2 ml: inaktiviran virus bolezni modrikastega jezika, serotip 1, sev BTV-1/ALG2006/01 E1, aluminijev hidroksid, saponin in tiomersal.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial label 100 ml and 240ml
PODATKI NA STIČNI OZ. PRIMARNI OVOJNINI Nalepka na viali 100 ml in 240 ml
Zero days.
KARENCA Karenca: nič dni.
After administration of a two-fold overdose, a rectal temperature increase up to 2.1 ºC may occur 1 day after the injection and then rectal temperatures return to normal values.
Po dajanju dvojnega odmerka se lahko 1 dan po injiciranju pojavi povišanje rektalne temperature do 2,1°C.
ATCvet code: QI02AA08 To stimulate active immunity against Bluetongue Virus, serotype 1 in cattle.
Za stimulacijo aktivne imunosti proti virusu bolezni modrikastega jezika, serotip 1, pri govedu.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label 20ml
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Vaccinate only healthy animals.
POSEBNO(A) OPOZORILO(A) Cepite samo zdrave živali.
After first vaccination a rectal temperature increase of up to 1.6°C may occur very commonly the 3rd day after the injection.
Zelo pogosto se tretji dan po prvem cepljenju lahko pojavi povišanje rektalne temperature, ki ne presega 1,6 °C.
After second and third vaccination a rectal temperature increase of up to 1.3°C and 2.8°C respectively may occur very commonly one day after the injection and then rectal temperatures return to normal values.
Zelo pogosto se en dan po injiciranju se lahko pojavi povišanje rektalne temperature, ki ne presega 1,3 °C (po drugem cepljenju) oziroma 2,8 °C (po tretjem cepljenju).
STATEMENT OF ACTIVE SUBSTANCES Per dose of 2 ml
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA ( MRL)
RP* ≥ 1
Rp-Vet..
The recommended dose of Stocrin for adults is 600 mg once a day.
Priporočeni odmerek zdravila Stocrin za odrasle je 600 mg enkrat na dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Stocrin on 28 May 1999.
Evropska komisija je dovoljenje za promet z zdravilom Stocrin, veljavno po vsej Evropski uniji, izdala 28. maja 1999.
What measures are being taken to ensure the safe and effective use of Stocrin?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Stocrin?
Other information about Stocrin
Druge informacije o zdravilu Stocrin
The full EPAR for Stocrin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Stocrin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Stocrin.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Stocrin.
In patients aged 3 to 17 years, the dose depends on body weight.
Pri bolnikih, starih od treh do 17 let, je količina odmerka odvisna od njihove telesne mase.
What is Stocrin and what is it used for?
Kaj je zdravilo Stocrin in za kaj se uporablja?
Stocrin must not be used in patients with severe liver disease.
Zdravila Stocrin ne smejo uporabljati bolniki z resnimi boleznimi jeter.
It is recommended that Stocrin be taken on an empty stomach and without food, preferably at bedtime.
Priporočljivo je, da se zdravilo Stocrin jemlje na prazen želodec in brez hrane, po možnosti pred spanjem.
What benefits of Stocrin have been shown in studies?
Kakšne koristi je zdravilo Stocrin izkazalo v študijah?
What are the risks associated with Stocrin?
Kakšna tveganja so povezana z zdravilom Stocrin?
Stocrin must be avoided if patients are taking certain medicines because it can increase their side effects or reduce their effectiveness, or because the combination may increase effects on the heart.
Uporabi zdravila Stocrin se je treba izogibati, če bolniki jemljejo določena zdravila, saj lahko okrepi njihove neželene učinke ali zmanjša njihovo učinkovitost ali pa kombinacija z njimi lahko okrepi učinke na srce.
Stocrin can affect the electrical activity of the heart and so must also not be used in patients with heart problems such as changes in heart rhythm and activity, slow heart rate or heart failure or other conditions that can affect the heart's electrical activity, or who have close relatives that have died suddenly from a heart condition or were born with heart problems.
Zdravilo Stocrin lahko vpliva na električno dejavnost srca in se zato ne sme uporabljati pri bolnikih s težavami s srcem, kot so spremembe srčnega ritma in aktivnosti, nizek srčni utrip, srčno popuščanje ali druge bolezni, ki lahko vplivajo na električno dejavnost srca, ali pri bolnikih, katerih bližnji sorodnik je nenadoma umrl zaradi bolezni srca ali pa ima prirojene težave s srcem.
It is not intended to provide practical advice on how to use Stocrin.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Stocrin has shown benefit in controlling HIV infection in three main studies involving over 1,100 adults.
Zdravilo Stocrin je pri obvladovanju okužbe z virusom HIV izkazalo koristi v treh glavnih študijah, v katere je bilo vključenih več kot 1 100 odraslih.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Stocrin have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Stocrin upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Stocrin approved?
Zakaj je bilo zdravilo Stocrin odobreno?
It also noted that there is little information on the benefits of treatment that includes a protease inhibitor in patients who have been treated with Stocrin in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients.
Poudarila je tudi, da je malo informacij o koristih zdravljenja z zaviralcem proteaze pri bolnikih, ki so bili v preteklosti zdravljeni z zdravilom Stocrin, ki je prenehalo biti učinkovito, čeprav ni dokazov, da zaviralci proteaze pri teh bolnikih ne bi bili učinkoviti.
The European Medicines Agency decided that Stocrin's benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older and recommended that it be approved for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Stocrin večje od z njim povezanih tveganj pri kombiniranem protivirusnem zdravljenju odraslih, mladostnikov in otrok, starih tri leta ali več, ki so okuženi z virusom HIV, in priporočila, da se odobri za uporabo v EU.
By blocking this enzyme, Stocrin, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Stocrin z zaviranjem tega encima v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
Stocrin does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Zdravilo Stocrin ne ozdravi okužbe z virusom HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
Similar results were seen in a study in 57 children aged between 3 and 16 years, given Stocrin in combination with nelfinavir and other antiviral medicines.
Podobne rezultate so ugotovili v študiji, ki je vključevala 57 otrok, starih med tri in 16 let, ki so prejemali zdravilo Stocrin v kombinaciji z nelfinavirjem in drugimi protivirusnimi zdravili.
The active substance in Stocrin, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Zdravilna učinkovina zdravila Stocrin, efavirenz, je nenukleozidni zaviralec reverzne transkriptaze (NNRTI).
Taking Stocrin with food may lead to an increase in the frequency of side effects.
Jemanje zdravila Stocrin skupaj s hrano lahko poveča pogostnost neželenih učinkov.
It is available as capsules, tablets and oral solution and must be given in combination with other antiviral medicines.
Na voljo je v obliki kapsul, tablet in peroralne raztopine, dajati pa ga je treba skupaj z drugimi protivirusnimi zdravili.
Stocrin is an antiviral medicine that is used together with other antiviral medicines to treat patients aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Stocrin je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje bolnikov, starejših od treh let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).